Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 300 mg aripiprazole. Abilify Maintena 400 mg
ABILIFY MAINTENA, , OTSUKA PHARMACEUTICAL CO LTD, ARIPIPRAZOLE 300 MG / SYR. Previous1Next ABILIFY MAINTENA. ARIPIPRAZOLE 300 MG / VIAL. ABILIFY
aripiprazole. ABILIFY MAINTENA 300 mg. ABILIFY MAINTENA 400 mg. Powder and solvent for prolonged-release suspension for injection. Re-evaluation. Adopted by the
Présentations du médicament ABILIFY MAINTENA. ABILIFY MAINTENA 300 mg : préparation pour suspension injectable à libération prolongée ; 1
Of the 2,649 patients exposed to ABILIFY MAINTENA, 1,316 patients have received at least 9 ABILIFY MAINTENA 400 mg/300 mg injections, (i.e
(ABILIFY MAINTENA) (300 mg and 400 mg vial) PrAbilify Maintena (aripiprazole) prolonged release suspension for injection 300 mg and 400 mg
aripiprazole. ABILIFY MAINTENA 300 mg. ABILIFY MAINTENA 400 mg. Powder and solvent for prolonged-release suspension for injection. Re-evaluation. Adopted by the
ID. altLabel. ARIPiprazole 300 MG Injection [Abilify]. Abilify Maintena 300 MG Injection.
Abilify Maintena 300 mg Suspension for Injection in Pre-filled Syringe
Comments